U.S. Army reports progress on COVID-19 vaccine that fights all variants
Dec 22, 2021
Animal studies already have shown that the new vaccine induces highly potent antibody responses against major variants.
Treatment for cannabis use disorder has decreased since 2004
Feb 27, 2024
For people with cannabis use disorder in 2004 to 2014, specialty treatment decreased in states with medical cannabis laws with dispensary provisions.
Members of Biden transition team call for new COVID-19 plan
Jan 06, 2022
Six former advisers published opinion articles Thursday in JAMA detailing what needs to be done now to put a plan in place.
Recent cancer may increase risk for Guillain-Barré syndrome
Mar 04, 2022
“It is important that people with cancer know the overall risk of developing Guillain-Barré is still very small,” an author said in a statement.
Moderna asks FDA to approve second booster for all adults
Mar 18, 2022
The Moderna request covers all adults to give federal health officials the freedom to determine who should get a second booster.
Most with Alzheimer’s disease, mild cognitive impairment would have been excluded from aducanumab...
Sep 16, 2021
Overall, 92.2, 91, and 85.5% of Medicare beneficiaries with Alzheimer’s disease-related disorders, Alzheimer’s disease, and mild cognitive impairment met at least one of the exclusion criteria.
Environmental Protection Agency finalizes stronger air quality standards
Feb 09, 2024
The agency estimates that the new standard will prevent up to 4,500 premature deaths in the first year of full enforcement.
eGFRcr-cys levels more strongly linked to adverse outcomes in seniors
Jan 29, 2024
Stronger and more uniform associations were seen for all-cause mortality and kidney failure with replacement therapy.
Adverse events associated with BNT162b2 vaccination ID’d
Aug 27, 2021
Vaccination with the Pfizer–BioNTech mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with an increased risk for myocarditis and lymphadenopathy, according...
Recommendations updated for management of heart failure
Apr 08, 2022
Sodium-glucose cotransporter-2 inhibitors are recommended for heart failure with reduced, mildly reduced ejection fraction.